Karyopharm Therapeutics | KPTI - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.27B 1000K 2026-06
Abbott USD 10.46B 1.15B 2026-06
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
GlaxoSmithKline GBP 5.8B 468M 2026-06
Incyte USD 973.64M 4.65B 2026-06
J&J USD 17.83B 388M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 10.2B 912M 2026-06
Novartis USD 9.29B 507M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Takeda JPY 1.02T 89.68B 2026-06
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
TG Therapeutics USD 218.66M 48.54M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Xencor USD 87.82M 5.44M 2026-06